Coppell Advisory Solutions LLC Invests $1.96 Million in Novo Nordisk A/S $NVO

Coppell Advisory Solutions LLC acquired a new stake in Novo Nordisk A/S (NYSE:NVO) during the 2nd quarter, Holdings Channel.com reports. The firm acquired 28,655 shares of the company’s stock, valued at approximately $1,963,000.

Several other hedge funds have also recently bought and sold shares of NVO. Jennison Associates LLC grew its position in Novo Nordisk A/S by 0.3% in the 2nd quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock valued at $1,303,466,000 after acquiring an additional 63,341 shares in the last quarter. Loomis Sayles & Co. L P grew its holdings in shares of Novo Nordisk A/S by 1.5% in the second quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock valued at $867,998,000 after purchasing an additional 187,789 shares in the last quarter. Kingstone Capital Partners Texas LLC increased its stake in Novo Nordisk A/S by 301,443.6% during the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock worth $690,560,000 after buying an additional 10,001,898 shares during the period. Sustainable Growth Advisers LP increased its stake in Novo Nordisk A/S by 11.7% during the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock worth $427,416,000 after buying an additional 649,390 shares during the period. Finally, State Street Corp lifted its holdings in Novo Nordisk A/S by 0.8% during the 2nd quarter. State Street Corp now owns 6,047,683 shares of the company’s stock worth $418,231,000 after buying an additional 47,430 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 0.3%

NYSE:NVO opened at $50.12 on Friday. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $109.88. The stock has a market cap of $223.79 billion, a P/E ratio of 14.57 and a beta of 0.67. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The stock has a 50-day simple moving average of $50.86 and a 200-day simple moving average of $58.36.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. The firm had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, September 9th. The Goldman Sachs Group lowered their target price on Novo Nordisk A/S from $60.00 to $54.00 and set a “buy” rating for the company in a research note on Friday, November 28th. BMO Capital Markets cut their price target on Novo Nordisk A/S from $50.00 to $46.00 and set a “market perform” rating on the stock in a report on Tuesday, November 25th. Zacks Research cut Novo Nordisk A/S from a “hold” rating to a “strong sell” rating in a research note on Wednesday, December 3rd. Finally, HSBC restated a “hold” rating and set a $54.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $53.33.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.